Implication of JAK1, JAK2, and JAK3 in the Realization of Proliferation and Differentiation Potential of Mesenchymal Progenitor Cells In Vitro

被引：3

作者：

Zyuz'kov, G. N. ^{[1
,2
]}

Zhdanov, V. V. ^{[1
]}

Udut, E. V. ^{[1
]}

Miroshnichenko, L. A. ^{[1
]}

Simanina, E. V. ^{[1
]}

Polyakova, T. Yu. ^{[1
]}

Chaikovskii, A. V. ^{[1
]}

Stavrova, L. A. ^{[1
]}

Udut, V. V. ^{[2
]}

Agafonov, V. I. ^{[1
]}

Burmina, Ya. V. ^{[1
]}

Danilets, M. G. ^{[1
]}

Minakova, M. Yu. ^{[1
]}

Dygai, A. M. ^{[1
]}

机构：

[1] ED Goldberg Res Inst Pharmacol & Regenerat Med, Tomsk, Russia

[2] Natl Res Tomsk State Univ, Tomsk, Russia

来源：

BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE | 2016年 / 161卷 / 02期

关键词：

signal pathways; JAK kinases; progenitor cells; regenerative medicine; pharmacological control; COLONY-STIMULATING FACTOR; FUNCTIONAL STIMULATION; ALKALOID SONGORINE; PRECURSOR CELLS; BRAIN ISCHEMIA; HYALURONIDASE; MECHANISMS; STATS; Z77;

D O I：

10.1007/s10517-016-3381-7

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Involvement of individual JAK kinases in the realization of growth potential of mesenchymal progenitor cells was examined in vitro. Important role of JAK2 and JAK3 in determining the initial level of mitotic activity of progenitor cells was established. The yield of fibroblast CFUF was suppressed under the effect of specific inhibitors of JAK kinases. Blockade of JAK3 increased the rate of progenitor element differentiation. JAK1 had no effect on proliferation and differentiation status of progenitor cells.

引用

页码：224 / 227

页数：4

共 50 条

[31] Delineation of the regions of interleukin-2 (IL-2) receptor β chain important for association of Jak1 and Jak3 -: Jak1-independent functional recruitment of Jak3 to IL-2Rβ
Zhu, MH
Berry, JA
Russell, SM
Leonard, WJ
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (17) : 10719 - 10725
[32] Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia
D Bellanger
V Jacquemin
M Chopin
G Pierron
O A Bernard
J Ghysdael
M-H Stern
Leukemia, 2014, 28 : 417 - 419
[33] Inhibitors of JAK2 and JAK3: an update on the patent literature 2010-2012
Dymock, Brian W.
See, Cheng Shang
EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (04) : 449 - 501
[34] INTERACTION OF JAK3 AND JAK1 TYROSINE KINASES WITH THE IL4 RECEPTOR COMPLEX
MALABARBA, MG
KIRKEN, RA
RUI, H
KAWAMURA, M
OSHEA, JJ
FARRAR, WL
JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 55 - 55
[35] Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia
Bellanger, D.
Jacquemin, V.
Chopin, M.
Pierron, G.
Bernard, O. A.
Ghysdael, J.
Stern, M-H
LEUKEMIA, 2014, 28 (02) : 417 - 419
[36] Mutations of JAK2, JAK3 and GATA1 in acute megakaryoblastic leukemia of Down syndrome
Hama, Asahito
Yagasaki, Hiroshi
Takahashi, Yoshiyuki
Matsumoto, Kimikazu
Kiyoi, Hitoshi
Kojima, Seiji
BLOOD, 2008, 111 (04) : 2493 - 2494
[37] JAK3 - A NOVEL JAK KINASE ASSOCIATED WITH TERMINAL DIFFERENTIATION OF HEMATOPOIETIC-CELLS
RANE, SG
REDDY, EP
ONCOGENE, 1994, 9 (08) : 2415 - 2423
[38] IMPLICATIONS OF RUXOLITINIB, JAK1/JAK2 INHIBITOR, ON THE GRAFT EFFECT AGAINST LEUKEMIA IN NK CELLS
Carmen, Mestre-Duran
Carla, Martin-Cortazar
Al-Fonso, Navarro-Zapata
David, Bueno
Laura, Clares-Villa
Alicia, Pernas
Karima, Al-akioui
Luisa, Sisinni
Blanca, Garcia-Solis
Victor, Galan
Nerea, Matamala
Adela, Escudero
Cristina, Ferreras
Antonio, Perez-Martinez
HAEMATOLOGICA, 2021, 106 (10) : 29 - 30
[39] THE JAK1/JAK2 INHIBITOR, RUXOLITINIB SUBSTANTIALLY AFFECTS NK CELL BIOLOGY
Schoenberg, K.
Janna, R.
Cornez, I.
Brossart, P.
Wolf, D.
BONE MARROW TRANSPLANTATION, 2014, 49 : S74 - S75
[40] The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib
Choy, E. H. S.
Miceli-Richard, C.
Gonzalez-Gay, M. A.
Sinigaglia, L.
Schlichting, D. E.
Meszaros, G.
de la Torre, I.
Schulze-Koops, H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (04) : 694 - 704

← 1 2 3 4 5 →